IL6 and melanoma: Melanoma susceptibility to immunotherapies is reduced by CAFs production of IL6 and induction of IL10 in melanoma cells, the latter inhibiting antigen-presenting cells and weakening the immune response (Terai et al., 2012; Simiczyjew et al., 2020).